Available studies suggest that omega-3 PUFAs exert pleiotropic effects on cognitive decline, mood, the cardiovascular system, bone and muscle health, vascular endothelium, and immune function.
EPA is a more important indicator of omega-3 PUFA intake than DPA or DHA, probably owing to the different ways it is incorporated into membrane phospholipids. The intake of EPA up to 3 g/d is safe and effective.
A recent meta-analysis of 149.051 individuals demonstrated that the cardiovascular risk reduction observed for omega-3 PUFAs is more prominent with EPA in monotherapy (doses ranging from 1.8 to 4.0 g/d) than with EPA + DHA. The meta-analysis confirmed the function of omega3 PUFAs, specifically EPA, in the current treatment for residual cardiovascular risk reduction in patients with atherosclerotic cardiovascular diseases.
You can read the open-access paper here: https://www.lidsen.com/journals/geriatrics/geriatrics-06-02-198
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.